Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Speculative but powerful catalyst-driven setup: FDA's 2026-06-17 signal that AMT-130 Phase 1/2 data could support an accelerated approval filing materially improved the regulatory path, with a possible Q3 2026 BLA narrative. Shares are up about 99% over 21 trading days, confirming strong market interest.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Price Behavior
Key Price Behavior Insights: • Lower highs • Support zone • Bounce risk Support Level: $39–$40 Resistance Level: $41–$41.5 QURE remains technically weak over the last month, with persistent lower highs, support around $39–$40, and only a tentative bounce setup if it can reclaim $41–$41.5.
Sentiment & News
Key News Insights: • AMT-130 Catalyst • FDA Timeline • Valuation Risk QURE is rallying on AMT-130 optimism and upcoming FDA milestones, but valuation, financing, and execution risks remain key.
AI Summary
QURE has shifted into a single-asset, event-driven bet on AMT-130, where the upside now depends less on cash runway (which extends to 2029) and more on FDA acceptance of the Phase I/II data and BLA path, while the recent financing and downtrend mean any regulatory slip could trigger a quick valuation reset.
Description
uniQure N.V. is a gene therapy company developing treatments for genetic and other severe diseases. Its lead program, etranacogene dezaparvovec (AMT-061), is in the Phase III HOPE-B trial for hemophilia B, and the broader pipeline includes clinical and preclinical candidates targeting central nervous system and neuromuscular disorders such as Huntington’s disease, Parkinson’s disease, temporal lobe epilepsy, ALS and forms of Alzheimer’s, as well as earlier-stage hemophilia approaches. The company was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Jun 25 | Jul 2 | QURE | uniQure N.V. | Speculative but powerful catalyst-driven setup: FDA's 2026-06-17 signal that AMT-130 Phase 1/2 data could support an accelerated approval filing materially improved the regulatory path, with a possible Q3 2026 BLA narrative. Shares are up about 99% over 21 trading days, confirming strong market interest. | Closed | -14.8% |
| Jun 17 | Jun 24 | QURE | uniQure N.V. | Selected for a very strong near-term regulatory catalyst: on 2026-06-17 the FDA signaled AMT-130 mid-stage data could support an accelerated approval filing, with uniQure planning a BLA submission. The stock broke out sharply with about +94% 21-day momentum, making it a high-risk but catalyst-backed short-term momentum idea. | Closed | +1.4% |
| Sep 29 | Oct 6 | QURE | uniQure N.V. | uniQure’s Phase I/II Huntington’s gene therapy trial showed a 75% slowing of progression, triggering a 250% price surge and near five-year high. Strong FDA alignment for BLA filing and robust capital provide near-term growth catalysts despite technical overbought conditions and dilution risk. | Closed | -10.9% |